Tenaya appoints interim PAO and reprices CEO underwater options to $1.21

Tenaya Therapeutics, Inc.

Tomohiro Higa appointed Interim Principal Accounting Officer effective Feb 6, 2025; he remains SVP Finance.
Board repriced CEO Faraz Ali's underwater options: new exercise price $1.21 per share on 915,875 shares.
Prior exercise prices ranged from $5.64 to $15.19; repricing contingent on retention through July 24, 2025.
If CEO exercises before retention date, he must pay the original higher exercise price.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Tomohiro Higa

Interim Principal Accounting Officer

TNYA · Tenaya Therapeutics, Inc.

Effective: 2025-02-06
Filed: February 7, 2025, 6:59 PM ET

Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tomohiro Higa was appointed as Interim Principal Accounting Officer at Tenaya Therapeutics, Inc..

Action: appointed
Role: Interim Principal Accounting Officer

Exact text from the filing

Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.

View on SEC.gov

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-016378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.